Suven Pharmaceutical ltd
Q4&FY21 Business Updates
Company Overview -
• Suven is an integrated Contract Development and Manufacturing Operations company
• Integrated CDMO company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing.
• Suven provides services to leading Global Life Science and Fine Chemical majors including Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations.
Financial Results -
Key Q4 Financial Highlights -
• Revenue - 2624 million ( 38%) ( y-o-y )
• EBITDA - 969 million ( 18%) ( y-o-y )
• EBITDA Margin - 37%
• PAT - 831 million ( 12%) ( y-o-y )
• PAT Margin - 31.37 %
Key FY21 Financial Highlights -
• Revenue - 10,239 million ( 20%) ( y-o-y )
• EBITDA - 4547 million (13.75%) ( y-o-y )
• EBITDA Margin - 44.4%
• PAT - 3623 million ( 14.3%) ( y-o-y )
• PAT Margin - 35.4%
• EBIT to Income - 41.32%
• EBITDA to Income - 44.41%
• PAT to Income - 35.38%
Key FY21 Businesswise Updates -
• CDMO Pharma - 33.11% ( y-o-y )
• CDMO Spec. chemicals -
• Formulations & Other Services - 7.38% ( y-o-y )
————————————————————————
Thank you for reading
Comments
Post a Comment